Add BrightSurf on Google Email

Beyond


Semaglutide significantly reduces risk of major kidney disease events, cardiovascular outcomes and mortality in patients with type 2 diabetes and chronic kidney disease, groundbreaking study reveals

A groundbreaking study reveals semaglutide significantly reduces the risk of major kidney disease events, cardiovascular outcomes, and all-cause mortality in patients with type 2 diabetes and chronic kidney disease. Semaglutide also shows improved safety and efficacy profiles.

SourceBeyond·JournalNew England Journal of Medicine·DateMay 24, 2024

Gas-related intestinal symptoms affect nearly all adults on a daily basis, and are associated with psychological distress and poorer quality of life, new multi-national survey finds

A multi-national survey of nearly 6,000 people found that gas-related symptoms are a common experience for most adults, with almost eight out of ten reporting symptoms in the previous 24 hours. The study also showed that these symptoms can have a significant impact on quality of life and mental health, particularly among younger people.

SourceBeyond·DateOct 2, 2021